Dysregulation of RIPK2-mediatedpathways is associated with inflammatory bowel disease,19 severe pulmonary sarcoidosis,20 multiple sclerosis,21 and cancer.22 We hypothesized that the ability to degradeRIPK2 only in cells that express cancer biomarkers would provide thebasis for cell-selective targeting. The gene discussed is RIPK2; the disease is cancer.